Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883528 | 0.93 | NAAA (0.43) | NAAAHIF1ATSHR | |
| SCHEMBL348397 | 0.86 | NAAA (0.34) | NAAAHIF1A | |
| SCHEMBL5884001 | 0.77 | APLNR (0.47) | HIF1ATSHR | |
| SCHEMBL4812712 | 0.75 | HRH1 (0.55) | NAAA | |
| SCHEMBL3547786 | 0.75 | HIF1A (0.34) | HIF1A | |
| SCHEMBL3545418 | 0.74 | AURKA (0.44) | HIF1A | |
| SCHEMBL5883075 | 0.74 | TSHR (0.37) | HIF1ATSHR | |
| SCHEMBL1258644 | 0.73 | NAAA (0.44) | NAAA | |
| SCHEMBL30045799 | 0.73 | CYP19A1 (0.48) | TSHR | |
| SCHEMBL7036030 | 0.71 | NAAA (0.47) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| CN-1418197-A | Piperidine and piperazine substituted N-hydroxycarboxamides as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | CN | disclosed |
| WO-2003014092-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| CN-1324347-A | Arylpiperzines as metalloproteinase inhibiting agents (MMP) and their use | ASTRA ZENECA LTD (SE) | 2001-11-28 | — | — | CN | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1109787-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000012478-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | NAAA 1907/4885HIF1A 906/4885TSHR 4597/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | NAAA 1165/4885HIF1A 1188/4885TSHR 4551/4885 |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | NAAA 386/4885HIF1A 1602/4885TSHR 1587/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | NAAA 570/4885HIF1A 894/4885TSHR 1688/4885 |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | NAAA 144/4885HIF1A 883/4885TSHR 1905/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | NAAA 379/4885HIF1A 1494/4885TSHR 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.